Table 2.
Steady state pharmacokinetics of lamivudine (150 mg bi-daily)
| Cmax (μg/ml) | Cmin (μg/ml) | Tmax (h) | AUC(0-t) (μg/ml-h) | t½ (h) | |
|---|---|---|---|---|---|
| Overall | 2.43 | 0.24 | 1.0 | 12.00 | 4.70 |
| n = 27 | (1.00–3.32) | (0.08–0.51) | (1.0–4.0) | (6.11–18.04) | (1.73–8.77) |
| CD4 counts cell/μl | |||||
| < 200 | 2.44 | 0.32 | 1.0 | 12.60 | 4.70 |
| n = 15 | (1.00–3.24) | (0.08–0.51) | (1.0–4.0) | (6.11–18.04) | (1.73–8.77) |
| ≥200 | 2.36 | 0.22 | 1.0 | 11.74 | 4.45 |
| n = 12 | (1.38–3.32) | (0.13–0.39) | (1.0–4.0) | (7.40–14.02) | (2.26–6.22) |
| Sex | |||||
| Males | 2.37 | 0.24 | 1.0 | 12.02 | 4.70 |
| n = 17 | (1.00–3.10) | (0.11–0.51) | (1.0–4.0) | (6.11–18.04) | (1.73–7.10) |
| Females | 2.57 | 0.23 | 1.0 | 11.47 | 3.93 |
| n = 10 | (1.28–3.32) | (0.08–0.41) | (1.0–2.0) | (7.09–15.33) | (2.22–8.77) |
| BMI (kg/m2) | |||||
| < 18.5 | 2.40 | 0.22 | 1.0 | 11.47 | 3.49 |
| n = 18 | (1.28–3.32) | (0.08–0.51) | (1.0–4.0) | (7.09–18.04) | (1.73–7.06) |
| ≥ 18.5 | 2.44 | 0.38 | 1.0 | 12.48 | 5.60 |
| n = 9 | (1.00–2.89) | (0.11–0.45) | (1.0–2.0) | (6.11–14.02) | (2.40–8.77) |
| Co-trimoxazole | |||||
| Yes | 2.38 | 0.18 | 1.0 | 12.48 | 3.24 |
| n = 15 | (1.00–2.96) | (0.08–0.51) | (1.0–4.0) | (6.11–18.04) | (1.73–8.77) |
| No | 2.46 | 0.23 | 1.0 | 11.46 | 4.90 |
| n = 12 | (1.28–3.32) | (0.13–0.45) | (1.0–2.0) | (7.09–15.41) | (3.00–7.10) |
Cmax, peak concentration; Cmin, minimum concentration; Tmax, time to attain Cmax; AUC, area under the plasma concentration vs. time curve; t½, half life. Values are shown as median and range given in parentheses